CTIS2023-510463-35-00招募中1 期
ETOP 22-22 ADEPPT: A multicentre, single-arm phase II trial of adagrasib in patients with KRASG12C-mutant NSCLC, including the elderly (=70 years) or patients with poor performance status - ETOP 22-22 ADEPPT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Most important inclusion criterias:- Histologically or cytologically confirmed stage IV NSCLC - KRASG12C-mutation by local testing (by tissue or ctDNA) - Prior treatment with at least one line of systemic therapy for NSCLC (e.g., platinum-based doublet chemotherapy and/or immune-checkpoint inhibition or both). - Life expectancy =12 weeks - Measurable disease according to RECIST v1.1 - Age =18 years with ECOG PS 2 (cohort 1), or age =70 years with ECOG PS 0-1 (cohort 2) - Adequate haematological, renal and liver function - Negative pregnancy test for patients of childbearing potential - Ability to comply with the trial protocol, in the investigator's judgment. -Written informed consent for protocol treatment must be signed and dated by the patient and the investigator prior to any trial-related intervention, including the submission of mandatory biomaterial.
排除标准
- •-Prior investigational therapy within 28 days or at least 5 half-lives before enrolment -Prior treatment with an agent targeting KRASG12C -Leptomeningeal disease or untreated brain metastases: – Patient should be neurologically stable for at least 2 weeks before enrolment, without the need for corticosteroids, except for prednisone (or its equivalent) at a dose of =10 mg daily – For patients with definitively treated brain metastases, a minimum of 2 weeks must have elapsed from the last day of radiotherapy - History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications. Any of the following cardiac abnormalities: – Unstable angina pectoris or myocardial infarction within 6 months prior to enrolment. – Symptomatic or uncontrolled atrial fibrillation within 6 months prior to enrolment. – Congestive heart failure =NYHA Class 3 within 6 months prior to enrolment. – Prolonged QTc interval >480 ms or family or medical history of congenital Long QT Syndrome -History of stroke or transient ischemic attack within 6 months prior to enrolment -Ongoing need for treatment with concomitant medication with any of the following characteristics: known risk of Torsades de Pointes; substrate of CYP3A with narrow therapeutic index; strong inducer of CYP3A and/or P-gp; strong inhibitor of BCRP; and proton pump inhibitors that cannot be switched to alternative treatment prior to enrolment -Known human immunodeficiency virus (HIV) infection -Acute or chronic hepatitis B or C infection. Note that the following are permitted: a. Patients treated for hepatitis C (HCV) with no detectable viral load at screening; b. Patients treated for HIV with no detectable viral load for at least 1 month prior to enrolment; and c. Patients with hepatitis B (HBV) receiving prophylaxis against reactivation of hepatitis B (either [HBsAg-positive with normal ALT and HBV DNA <2,000 IU/mL or <10,000 copies/mL] or [HBsAg-negative and anti-HBcAg-positive]) -Women who are pregnant or in the period of lactation -Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study -Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
研究者
相似试验
进行中（未招募）
1 期
STUDY OF ATEZOLIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCEREXTENSIVE-STAGE SMALL CELL LUNG CANCER (es-SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001146-17-ITROCHE SPA150
进行中（未招募）
1 期
STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA NOT PREVIOUSLY TREATED WITH SYSTEMIC THERAPYnresectable hepatocellular carcinoma (HCC)MedDRA version: 21.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864EUCTR2020-001973-66-ITROCHE SPA150
进行中（未招募）
1 期
The study will evaluate the safety and efficacy of a combined therapy consisting of immuntherapy and radiation prior to radical cystectomy in patients with locally advanced urothelial bladder cancerocally advanced urothelial bladder cancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001823-38-DETechnische Universität München, Fakultät für Medizin vertreten durch den Dekan33
已完成
2 期
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.Cancer - MyelomaMultiple MyelomaACTRN12616000894493Professor Andrew Spencer40
进行中（未招募）
1 期
A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe - RAMSETEPatients with histologically confirmed advanced (unresectable or metastatic) non syndromic NET from foregut, midgut and hindgut, with exclusion of pancreatic NET, who have progressed within 12 months prior to study enrollment and with measurable disease at baseline.Patients with poorly differentiated tumours are excluded.MedDRA version: 9.1Level: LLTClassification code 10052399Term: Neuroendocrine tumourEUCTR2008-006182-88-DEovartis Pharma Services AG69